Stockreport

Nuvation Bio: Rollout Data Of Ibtrozi Support A Modest Buy [Seeking Alpha]

Nuvation Bio Inc. Class A  (NUVB) 
PDF IBTROZI's patient starts stabilized at 3.3/day in late 2025, with revenue projections reaching ~$1B by 2030 based upon conservative assumptions. NUVB holds ~$620M in [Read more]